Document is current
Any future updates will be listed below
-
Authors
Ilioska, Iva https://orcid.org/0000-0001-6251-8196
Oldehinkel, Marianne
Llera, Alberto https://orcid.org/0000-0002-8358-8625
Rovný, Maroš
Mei, Ting
Kia, Seyed Mostafa https://orcid.org/0000-0002-7128-814X
Floris, Dorothea L.
Tillmann, Julian
Holt, Rosemary J.
Loth, Eva https://orcid.org/0000-0001-9458-9167
Charman, Tony https://orcid.org/0000-0003-1993-6549
Murphy, Declan G. M. https://orcid.org/0000-0002-6664-7451
Ecker, Christine
Banaschewski, Tobias https://orcid.org/0000-0003-4595-1144
Mennes, Maarten
Beckmann, Christian F.
Marquand, Andre https://orcid.org/0000-0001-5903-203X
Buitelaar, Jan K. https://orcid.org/0000-0001-8288-7757
Fornito, Alex
-
Funding
Funding for this research was provided by:
Radboud Universitair Medisch Centrum
ZonMw (452172019)
Innovative Medicines Initiative (115300)
Innovative Medicines Initiative (777394)
EC | Seventh Framework Programme (FP7/2007-2013)
EC | Horizon 2020 Framework Programme (643051)
EC | Horizon 2020 Framework Programme (642996)
Sylvia and Charles Viertel Charitable Foundation (3274306)
- License Information
-
More Information
Article History
Received: 8 September 2025
Accepted: 22 April 2026
First Online: 1 June 2026
Competing interests
: J.K.B. has been in the past 3 years a consultant to, member of advisory board of and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents or royalties. T.C. has served as a paid consultant to F. Hoffmann-La Roche and Servier and has received royalties from Sage Publications and Guilford Publications. J.T. has acted as a paid consultant and is a current employee of F. Hoffmann-La Roche AG. C.F.B. is a director and shareholder of SBGNeuro. The other authors declare no competing interests.
